March 4th, 2014
Drug makers spending less on MD speakers By Charl
By Charles Ornstein, Eric Sagara and Ryann Grochowski Jones
Boston Globel (ProPublica)
Payments decline as scrutiny from public increases
Some of the nationís largest pharmaceutical companies have slashed payments to health professionals for promotional speeches amid heightened public scrutiny of such spending, a ProPublica analysis shows. Eli Lilly and Co.ís payments to speakers dropped by 55 percent, from $47.9 million in 2011 to $21.6 million in 2012.
Pfizerís speaking payments fell 62 percent over the same period, from nearly $22 million to $8.3 million. And Novartis, the largest US drug maker as measured by 2012 sales, spent 40 percent less on speakers that year than it did between October 2010 and September 2011, reducing payments from $24.8 million to $14.8 million.